Guidelines for PMR Favor Lowest Effective Dose of GCs as Initial Therapy.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 26, doi. 10.1177/155989771451018
- By:
- Publication type:
- Article
Works matching IS 15598977 AND DT 2014 AND VI 14 AND IP 51
Results: 18
1
2
New Approaches to Treating LN.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 24, doi. 10.1177/155989771451017
- By:
- Publication type:
- Article
3
Gout Guidelines: The Good, the Bad, and the Future.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 21, doi. 10.1177/155989771451016
- By:
- Publication type:
- Article
4
Advances in the Treatment of Hepatitis C.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 19, doi. 10.1177/155989771451015
- By:
- Publication type:
- Article
5
MEASURE 1: Secukinumab an Effective Treatment for Active AS.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 18, doi. 10.1177/155989771451014
- By:
- Publication type:
- Article
6
Negative Results End Development Program of Treating JIA with GLM.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 17, doi. 10.1177/155989771451013
- By:
- Publication type:
- Article
7
FUTURE 1: Secukinumab Inhibits Radiographic Disease Progression in PsA.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 15, doi. 10.1177/155989771451012
- By:
- Publication type:
- Article
8
Infliximab Biosimilar Appears Safe and Effective Compared with Infliximab for RA.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 11, doi. 10.1177/155989771451007
- By:
- Publication type:
- Article
9
Efficacy of Secukinumab Sustained over Time for Treatment of Active PsA.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 14, doi. 10.1177/155989771451011
- By:
- Publication type:
- Article
10
APR Improves PsA Symptoms Out to Week 104.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 12, doi. 10.1177/155989771451009
- By:
- Publication type:
- Article
11
Flare-Free Withdrawal of TNFis Possible in Patients with RA and Stable Low Disease Activity.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 11, doi. 10.1177/155989771451008
- By:
- Publication type:
- Article
12
Triple Therapy More Cost-effective than Biologic First in Patients Who Fail MTX.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 13, doi. 10.1177/155989771451010
- By:
- Publication type:
- Article
13
Lesinurad Provides Additional Lowering of SUA in Gout.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 10, doi. 10.1177/155989771451006
- By:
- Publication type:
- Article
14
Preventing GC-Induced Bone Loss in Women with RA.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 9, doi. 10.1177/155989771451005
- By:
- Publication type:
- Article
15
GR Agonist Improves Responses in RA.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 8, doi. 10.1177/155989771451004
- By:
- Publication type:
- Article
16
Sifalimumab Slows Disease Activity in SLE.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 7, doi. 10.1177/155989771451003
- By:
- Publication type:
- Article
17
Secukinumab is Effective Treatment for Active PsA.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 6, doi. 10.1177/155989771451002
- By:
- Publication type:
- Article
18
New Approaches to Corticosteroid Resistance.
- Published in:
- MD Conference Express, 2014, v. 14, n. 51, p. 4, doi. 10.1177/155989771451001
- By:
- Publication type:
- Article